LB Pharmaceuticals Inc Common Stock (LBRX) Research

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Market snapshot

Symbol
LBRX
Price
$30.00
Day change
-0.17%
Market cap
$860.3M
P/E ratio
-21.63x
52-week range
13.36-33.47
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$39.50

Peer companies

  • Altimmune, Inc. (ALT)
  • Annexon, Inc. (ANNX)
  • Aura Biosciences, Inc. (AURA)
  • Autolus Therapeutics plc (AUTL)
  • DBV Technologies S.A. (DBVT)
  • Design Therapeutics, Inc. (DSGN)
  • Korro Bio, Inc. (KRRO)
  • Larimar Therapeutics, Inc. (LRMR)

Open LB Pharmaceuticals Inc Common Stock (LBRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.